Lundbeck Feed

2025-12-06 18:00:00 H. Lundbeck A/S: Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

2025-12-02 08:00:00 H. Lundbeck A/S: Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting 44,32 DKK | +1,23% | 13,4 MDKK

2025-11-26 17:23:54 H. Lundbeck A/S: ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES") 44,06 DKK | +1,71% | 24,0 MDKK

2025-11-14 12:44:59 H. Lundbeck A/S: ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES") AND MAR ARTICLE 17 (INSIDE INFORMATION) 45,52 DKK | -0,18% | 25,3 MDKK

2025-11-14 08:55:30 H. Lundbeck A/S: Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine 45,52 DKK | -0,18% | 25,3 MDKK

2025-11-11 15:34:30 H. Lundbeck A/S: Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments 44,38 DKK | -4,52% | 156 MDKK

2025-11-11 15:21:59 H. Lundbeck A/S: Lundbeck raises financial guidance for 2025 44,38 DKK | -4,52% | 156 MDKK

2025-10-27 09:00:00 H. Lundbeck A/S: Lundbeck and OpenAI join forces to unlock innovation and boost productivity 46,26 DKK | +0,09% | 22,5 MDKK

2025-10-20 09:00:00 H. Lundbeck A/S: Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions 45,68 DKK | +0,40% | 10,9 MDKK

2025-10-13 08:00:00 H. Lundbeck A/S: Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies 45,66 DKK | -0,48% | 33,2 MDKK

2025-10-02 09:00:00 H. Lundbeck A/S: Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025 44,76 DKK | -4,28% | 38,8 MDKK

2025-09-20 08:00:11 H. Lundbeck A/S: Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD

2025-09-11 08:00:00 H. Lundbeck A/S: Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine 42,92 DKK | +2,68% | 37,5 MDKK

2025-09-09 14:30:00 H. Lundbeck A/S: Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025 41,84 DKK | +1,41% | 14,8 MDKK

2025-08-25 09:00:00 H. Lundbeck A/S: Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy 39,04 DKK | -2,11% | 12,8 MDKK

2025-08-13 18:40:55 H. Lundbeck A/S: Guidance raised based on solid H1 results and continued strong expectations for the full year 2025 38,92 DKK | +9,39% | 56,4 MDKK

2025-08-13 18:34:47 H. Lundbeck A/S: Lundbeck raises financial guidance for 2025 38,92 DKK | +9,39% | 56,4 MDKK

2025-07-18 23:24:18 H. Lundbeck A/S: Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD)

2025-06-24 08:00:00 H. Lundbeck A/S: Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia 36,36 DKK | -0,22% | 12,9 MDKK

2025-06-21 13:25:00 H. Lundbeck A/S: New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

2025-06-21 13:20:00 H. Lundbeck A/S: New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

2025-05-22 17:31:56 H. Lundbeck A/S: Lundbeck successfully places a EUR 500 million Eurobond 37,12 DKK | +3,28% | 46,8 MDKK

2025-05-14 07:17:40 H. Lundbeck A/S: Lundbeck raises financial guidance following strong start to the year with strategic brands growth of +24% CER 33,70 DKK | +10,35% | 76,3 MDKK

2025-05-08 08:00:00 H. Lundbeck A/S: Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston 29,96 DKK | -3,29% | 12,6 MDKK

2025-05-06 08:00:00 H. Lundbeck A/S: Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer 31,36 DKK | -1,69% | 11,4 MDKK

2025-04-04 09:00:00 H. Lundbeck A/S: Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting 30,32 DKK | -5,43% | 24,0 MDKK

2025-03-31 11:00:16 H. Lundbeck A/S: Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention 34,70 DKK | -5,50% | 19,7 MDKK

2025-03-26 12:28:42 H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office 38,34 DKK | -4,15% | 17,9 MDKK

2025-03-13 09:00:00 H. Lundbeck A/S: Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older 39,24 DKK | +0,26% | 10,2 MDKK

2025-03-10 09:01:39 H. Lundbeck A/S: Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan 39,60 DKK | +0,66% | 15,2 MDKK

2025-02-25 10:00:02 To the shareholders of H. Lundbeck A/S 40,20 DKK | +0,95% | 18,0 MDKK

2025-02-21 13:27:48 H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties 39,74 DKK | +0,66% | 20,5 MDKK

2025-02-12 09:00:00 H. Lundbeck A/S: Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA 43,46 DKK | -1,27% | 24,3 MDKK

2025-02-05 16:40:11 H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties 44,86 DKK | -2,10% | 87,9 MDKK

2025-02-05 07:46:20 H. Lundbeck A/S: Lundbeck Annual Report 2024 44,86 DKK | -2,10% | 87,9 MDKK

2025-02-05 07:23:57 H. Lundbeck A/S: Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER) 44,86 DKK | -2,10% | 87,9 MDKK

2025-02-04 17:10:42 H. Lundbeck A/S: Lundbeck announces changes to the Board of Directors 44,86 DKK | -2,10% | 87,9 MDKK

2025-01-30 09:00:00 H. Lundbeck A/S: Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies 43,24 DKK | +0,98% | 15,5 MDKK

2025-01-09 14:07:30 H. Lundbeck A/S: Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD 41,36 DKK | +0,49% | 15,5 MDKK

2024-12-05 13:00:00 H. Lundbeck A/S: Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations 44,34 DKK | +1,00% | 16,4 MDKK

2024-12-03 08:00:00 H. Lundbeck A/S: Efficacy of Vyepti highlighted by new clinical trial results in severe migraine 44,14 DKK | +2,08% | 18,0 MDKK

2024-12-02 15:08:21 H. Lundbeck A/S: Lundbeck completes acquisition of Longboard 43,24 DKK | -1,73% | 17,2 MDKK

2024-11-28 07:56:40 H. Lundbeck A/S: Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled 43,96 DKK | -0,54% | 9,19 MDKK

2024-11-27 08:00:00 H. Lundbeck A/S: Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy 44,20 DKK | +0,68% | 10,3 MDKK

2024-11-13 07:29:55 H. Lundbeck A/S: Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 45,42 DKK | +5,14% | 62,5 MDKK

2024-10-31 12:44:28 H. Lundbeck A/S: Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention 44,66 DKK | -0,40% | 49,0 MDKK

2024-10-23 09:01:22 H. Lundbeck A/S: Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth 44,42 DKK | -4,76% | 66,1 MDKK

2024-10-14 12:30:44 H. Lundbeck A/S: Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline 48,20 DKK | -0,70% | 270 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Lundbeck

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden